Genes related to cancer pathways were downregulated upon atezolizumab treatment, including angiogenic factors for tumor vascularization (TNK1, AREG and KDR), proto-oncogenes (RET and MET) and tumor cell survival/migration/invasion (CDH1, RARA, WNK2, WNT4A, WNT9A, TGFB2, EGF, and LAMA3) (Figure 3E). This evidence concerns the gene WNT9A and neoplasm.